Article
FGFR a promising druggable target in cancer: Molecular biology and new drugs.
Critical reviews in oncology/hematology - 1 May 2017
Porta Rut, Borea Roberto, Coelho Andreia, Khan Shahanavaj, Araújo António, Reclusa Pablo, Franchina Tindara, Van Der Steen Nele, Van Dam Peter, Ferri Jose, Sirera Rafael, Naing Aung, Hong David, Rolfo Christian
Abstract excerpt
INTRODUCTION: The Fibroblast Growth Factor Receptor (FGFR) family consists of Tyrosine Kinase Receptors (TKR) involved in several biological functions. Recently, alterations of FGFR have been reported to be important for progression and development of several cancers. In this setting, different studies are trying to evaluate the efficacy of different therapies targeting FGFR. AREAS COVERED: This review summarizes...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.